Extended Data Fig. 6: Presence of TLPCs and hepatocyte senescence in human livers.

a, Immunostaining for p21 or HNF4α and CK19 in patient biopsies from the indicated human liver disease indications. Quantifications for p21⁺ hepatocytes and HNF4α⁺CK19⁺ TLPCs are shown in Fig. 1. Scale bars, 100 µm. b, Immunostaining for p21 and CK19 in the indicated human liver biopsies. Scale bars, 50 µm. c, Quantification of p21⁺ BECs in the indicated liver biopsies. Data represent mean ± SD. n = patients. Unpaired two-tailed t tests were used (vs. healthy, n = 4): alcoholic steatohepatitis (ASH) cirrhosis (n = 4, *P = 0.0495)): non-alcoholic steatohepatitis (NASH) cirrhosis (n = 4, P = 0.2207), Hepatitis (Hep)B cirrhosis (n = 4, ***P = 0.0009), HepC cirrhosis (n = 4, **P = 0.0031). d, Immunostaining showing HNF4α⁺CK19⁺ TLPCs within different BEC populations in the indicated biopsies (BD, bile duct; DR, ductular reaction: CoH, canals of Hering). Scale bars, 50 µm.